Abstract Library

#4670 The efficacy of first-line combination therapy with everolimus plus lanreotide for gastroenteropancreatic neuroendocrine tumour with a poor prognostic factor: Updated and subgroup analysis of the phase III study, STARTER-NET (JCOG1901)

Introduction: Everolimus monotherapy provided a limited median progression-free survival (PFS) for gastroenteropancreatic neuroendocrine tumours (GEP-NETs), there remains a necessity for better therapeutic approaches.

Conference:

Presenting Author:

Authors: Hijioka S, Honma Y, Machida N, Mizuno N, Hamaguchi T,

Keywords: everolimus, lanreotide, PFS, RCT,

#4658 The nutritional status worsens over 5 years in patients with gastroenteropancreatic neuroendocrine tumours on treatment with somatostatin analogues

Introduction: Malnutrition is common in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with monthly somatostatin analogues (SSAs). Ideally all malnourished patients are offered nutritional support. However, clinical guidelines and data on the development and progression of malnutrition is lacking.

Conference:

Presenting Author: Clement D

Authors: Soran V, Srirajaskanthan R, Cananea E, Martin W, Minott S,

Keywords: gastroenteropancreatic neuroendocrine tumour, malnutrition, somatostatin analogue,

#4590 Association of SST5TMD4 and SST5TMD5 expression with metastasis and poor prognostic markers in gastroenteropancreatic neuroendocrine tumours

Introduction: The expression of the somatostatin receptor isoform SST5TMD4 is linked to poorer prognosis in somatotropinomas, as well as in breast and thyroid cancers, and it is notably overexpressed in gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

Conference:

Presenting Author: Pedraza-Arevalo S

Authors: Pedraza-Arévalo S, Díaz-Pérez J, Garcia-Carbonero R, Villabona C, Capdevila J,

Keywords: GEP-NET, somatostatin, truncated receptor, metastasis,

#4579 Real-world effectiveness of lanreotide autogel in patients with advanced gastroenteropancreatic neuroendocrine tumours with antigen Ki-67 proliferation index above and below 10%: The KINETICS study

Introduction: The somatostatin analogue lanreotide is an established treatment option for patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) with a Ki-67 proliferation index (Ki-67)

Conference:

Presenting Author: Vandamme T

Authors: Vandamme T, Gerard L, Del Olmo-Garcia M, de Mestier L, Kiesewetter B,

Keywords: effectiveness, gastroenteropancreatic neuroendocrine tumour, GEP-NET, Ki-67 proliferation index, Ki-67, lanreotide, somatostatin analogue, somatostatin, real-world,

#4574 Long-acting somatostatin analogue injections for treating gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and acromegaly: BackSOM – A patient preference study

Introduction: Long-acting somatostatin analogues, lanreotide and octreotide, are indicated for first-line treatment of GEP-NETs and acromegaly. Lanreotide was approved in 2007 in Europe, and is supplied as a prefilled, ready-to-use syringe (LAN-PF). In 2021, a generic form of lanreotide was released and supplied in a syringe requiring assembly (LAN-RA). To ensure patient compliance with treatment, it is important to understand their injection experiences.

Conference:

Presenting Author: Hernando Cubero J

Authors: Rodien-Louw C, Simo-Servat A, Dubois M, Sheppard J, McDonnell M,

Keywords: gastroenteropancreatic neuroendocrine tumour, GEP-NET, acromegaly, lanreotide, LA-SSA, somatostatin, patient preference,